A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

A paper published Wednesday offers the strongest evidence yet that this is more than just anecdote, or a placebo effect: It ...

Novo Nordisk’s annual results are out and they show the Danish pharmaceutical juggernaut earnt 290.4 billion Danish kroner ... customers using their drug Ozempic, which has caused a revolution ...

Some people who use semaglutide (Ozempic, others) have noted sagging skin in the buttocks, calling it “Ozempic butt.” While lifestyle modifications may help prevent this weight loss side ...

Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending ... a new Canadian study suggests. Health News // 4 days ago COVID-19 may attack arteries, increase risk to heart ...

Weight loss from GLP-1 meds can cause faces to sag, spurring a big uptick in plastic surgeries to correct so-called 'Ozempic face' Nose jobs, facelifts and eye lifts still top the list of most ...

Denmark is home to Novo Nordisk (NYSE:NVO), the company behind Ozempic and Wegovy, two of the most in-demand drugs in the U.S. for weight loss and diabetes treatment. With demand for those drugs ...